Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Tesamorelin vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin and Tesamorelin + Ipamorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (FDA-Approved / FDA-Approved (component)). On the catalogued data layer Tesamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tesamorelin's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tesamorelin

FDA-Approved

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Tesamorelin Tesamorelin + Ipamorelin
Class GHRH analog (FDA-approved) FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route SC injection SC injection
Half-life ~26 min Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) 2 mg SC daily (FDA label) 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier FDA-Approved FDA-Approved (component)
Research depth 127 indexed (PubMed 84 · CT 23 · EPMC 20) —
Availability Prescription Compounding Restricted
Reported risks Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tesamorelin or Tesamorelin + Ipamorelin?

Tesamorelin and Tesamorelin + Ipamorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (FDA-Approved / FDA-Approved (component)). On the catalogued data layer Tesamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tesamorelin's evidence base is currently denser.

What is the difference between Tesamorelin and Tesamorelin + Ipamorelin?

Tesamorelin is classed as GHRH analog (FDA-approved); Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Tesamorelin, ~26 min; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Tesamorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, Tesamorelin or Tesamorelin + Ipamorelin?

Tesamorelin and Tesamorelin + Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.

Which is more accessible, Tesamorelin or Tesamorelin + Ipamorelin?

Tesamorelin is FDA-approved and Tesamorelin + Ipamorelin is not. Catalog status: Tesamorelin, Prescription; Tesamorelin + Ipamorelin, Compounding Restricted.

Are Tesamorelin and Tesamorelin + Ipamorelin ever combined?

Tesamorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…